Skip to Main Content

Author Details

Kevin H Lin
Duke University
2014
15
10
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36918588Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis.Nat Commun2023
35668193P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.Nat Cancer2022
34706244ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells.Cell Rep2021
32203462Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer.Nat Genet2020
32826232The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.Cancer Discov2020
32553168Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.Cell Rep2020
30773463Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity.Cell Metab2019
31517048Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models.Sci Adv2019
30323337Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers.Nat Commun2018
30158527Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity.Nat Commun2018
29931016An acoustofluidic trap and transfer approach for organizing a high density single cell array.Lab Chip2018
28746882A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Cell Rep2017
27283158Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.Sci Rep2016
26392303Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.Nat Commun2015
25538080RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.Sci Signal2014
  • 1 - 15 of 15

Recommended Authors

Amanda d'Almeida
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2018
Number of shared co-authors 0
Veronique Litalien
Walter and Eliza Hall Institute of Medical Research
Career Start Year 2016
Number of shared co-authors 0
Anna Senina
Huntsman Cancer Institute, The University of Utah
Career Start Year 2013
Number of shared co-authors 0
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 0
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 5
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Brett M Stevens
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 1
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 0
Malia B Potts
St. Jude Children's Research Hospital
Career Start Year 2004
Number of shared co-authors 0
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Jonathan R Dry
Present Address: Tempus Labs Inc.
Career Start Year 2003
Number of shared co-authors 2
Justin Cidado
Oncology R&D
Career Start Year 2003
Number of shared co-authors 0
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Career Start Year 2002
Number of shared co-authors 4
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 4
Phillip M Clair
Huntsman Cancer Institute, The University of Utah
Career Start Year 2001
Number of shared co-authors 0
Rose Hurren
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 0
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 0
Mathew J Garnett
Wellcome Sanger Institute
Career Start Year 1998
Number of shared co-authors 7
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 0
Andrei Goga
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 0
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 5
David E Root
Broad Institute of Harvard and MIT
Career Start Year 1993
Number of shared co-authors 7
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 5
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 2
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 0
Marcela Gronda
Princess Margaret Cancer Centre
Career Start Year 1985
Number of shared co-authors 0
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 5

Collaborators

Kris C Wood
Duke University
Co-authored papers 15
Gray R Anderson
Duke University
Co-authored papers 5
Peter S Winter
Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School
Co-authored papers 5
Abigail Xie
Duke University
Co-authored papers 4
Lorin Crawford
Center for Computational Molecular Biology, Brown University
Co-authored papers 3
Merve Cakir
Quantitative Biosciences Institute (QBI), University of California san francisco
Co-authored papers 3
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Co-authored papers 3
Jacob P Hoj
Duke University
Co-authored papers 3
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Co-authored papers 3
Antoine Forget (CM4AI)
University of California San Francisco
Co-authored papers 3
Yeong-Ran Ahn
Duke University
Co-authored papers 2
Emanuel F Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 2
Jiaxing Lin
Peking University People's Hospital
Co-authored papers 2
Min Lu
Shangrao Hospital Affiliated to Nanchang University
Co-authored papers 2
Ashutosh Chilkoti
Duke University
Co-authored papers 2
Mariaelena Pierobon
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 2
Christopher F Bassil
Duke University School of Medicine Durham
Co-authored papers 2
David A Rizzieri
Duke University Medical Center
Co-authored papers 2
Xinghai Li
Duke University
Co-authored papers 2
Reinaldo Dal Bello
Universite Paris Cite, INSERM, CNRS
Co-authored papers 2
Nina Fenouille
Universite Paris Cite, INSERM, CNRS
Co-authored papers 2
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Co-authored papers 2
Timothy S Pardee
Comprehensive Cancer Center of Wake Forest Baptist Health, Medical Center Boulevard
Co-authored papers 2
Gaetano Sodaro
Universite Paris Cite, INSERM, CNRS
Co-authored papers 2
Amy E Decker
Duke University
Co-authored papers 1
Deborah M Muoio
Co-authored papers 1
Bryann Pardieu
Universite de Paris, INSERM, CNRS
Co-authored papers 1
Justine Pasanisi
INSERM UMR , St Louis Hospital, University of Paris
Co-authored papers 1
Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 1
Marie-H??l??ne Schlageter
Universite de Paris, U1 INSERM
Co-authored papers 1
Release 1.2